Search Clinical Trials in the European Union
Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 525 trials
Actinic Keratosis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesDermatology
Functional Dyspepsia3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine
Alcohol-Associated Hepatitis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine
Non-Specific Low Back Pain1-2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesInfectious DiseasesOrthopedics and Traumatology
Urethral Posterior Valve>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPediatricsUrology
Acute Kidney Injury>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyInternal MedicineNephrology
Chickenpox6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics
Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology
Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology
Primary Biliary Cholangitis3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesHepatologyInternal Medicine
Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology
Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology
Crohn's Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine
Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology
Systemic Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineRheumatology
Recurrent Acute Lymphocytic Leukaemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology
ANCA-associated VasculitisRapid-Progressive Glomerulonephritis≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyRheumatology
Cryoglobulinemia Vasculitis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInfectious DiseasesRheumatology
Wrist Osteoarthritis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOrthopedics and TraumatologyRheumatology